Liraglutide was the first GLP1-RA to demonstrate significant positive cardiovascular outcomes in the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial [16]. The gene discussed is GCG; the disease is diabetes mellitus.